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Abstract
The purpose of this study was to examine the relationship of plasma 25-hydroxyvitamin D (25(OH)
D) concentrations to prostate cancer within a large multiethnic cohort in Hawaii and California using
a nested case-control design. The study included 329 incident prostate cancer cases of African
American, Native Hawaiian, Japanese, Latino, and White ancestry, and 656 controls matched on age,
race/ethnicity, date/time of blood collection, and fasting status. Conditional logistic regression was
used to estimate odds ratios (OR) and 95% confidence intervals (95% CI). No association with
prostate cancer risk was found in an analysis based on quartiles of 25(OH)D. When clinically defined
cutpoints were used, there was no increased risk for the lowest 25(OH)D concentration (OR for <20
vs. 30–<50 ng/ml = 1.10, 95% CI = 0.68-1.78), while there was a suggestive increased risk for higher
concentrations (OR for ≥50 ng/ml = 1.52, 95% CI = 0.92-2.51). The findings from this prospective
study of men in the Multiethnic Cohort do not support the hypothesis that vitamin D lowers the risk
of prostate cancer. Further follow-up is warranted to determine whether the findings are consistent
across ethnic groups.
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1. Introduction
Ecological studies showing that regions with a higher exposure to ultraviolet radiation tend to
have lower prostate cancer mortality rates have generated and supported the hypothesis that
vitamin D protects against prostate cancer.1-3 In vitro human cell studies have also
demonstrated that vitamin D metabolites suppress the growth and stimulate the differentiation
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of prostate cancer cells.4,5 To test this hypothesis in prospective epidemiologic studies,
investigators have measured prediagnostic serum or plasma 25-hydroxyvitamin D (25(OH)D)
concentrations, since circulating 25(OH)D is considered the best estimate of vitamin D status.
6 However, the associations with prostate cancer have been inconsistent.7-16 Furthermore, an
IARC Working Group recently reviewing 11 publications on circulating 25(OH)D and prostate
cancer risk reported that the findings in general do not offer clear support for the vitamin D
hypothesis.17
To further address this hypothesis, we examined the association between plasma 25(OH)D
concentration and prostate cancer risk in a nested case-control study within a large cohort in
Hawaii and California. Since skin pigmentation influences vitamin D status,18 studying this
association with multiple racial/ethnic groups provides a wide range of vitamin D
concentrations; most previous studies on this exposure and prostate cancer have been
conducted in ethnically homogeneous groups.
2. Materials and methods
2.1. Study population
The Multiethnic Cohort Study enrolled more than 215,000 adults (45-75 years) living in Hawaii
and California who completed a 26-page mailed questionnaire in 1993-1996.19 The study was
approved by the review boards of the University of Hawaii and the University of Southern
California. The study targeted five racial/ethnic groups: African Americans, Native Hawaiians,
Japanese Americans, Latinos, and Whites. A prospective biorepository was developed
primarily between 2001 and 2006.20 More than 67,000 participants who gave informed consent
to participate provided blood and/or urine specimens as well as updated information on a few
items from the baseline questionnaire.
2.2. Selection of cases and controls
Incident prostate cancer cases were identified through linkage to the tumor registries covering
the states of Hawaii and California, which are part of the Surveillance, Epidemiology and End
Results (SEER) Program of the National Cancer Institute. For this nested case-control study,
cases were defined as men who were diagnosed with invasive prostate cancer after blood
collection up to the 2006 tumor registry linkage. Advanced prostate cancers were defined as
all cancers that were regional or metastatic (not in situ or localized) while high grade cancers
were based on Gleason score ≥7 (categorized as poorly differentiated). During the follow-up
period, 467 eligible prostate cancer cases were identified. For each case, two controls were
randomly selected from a pool of potential controls in the biorepository who were alive and
free of prostate cancer at the age of the case's diagnosis and who matched the case on location
(Hawaii or California), race/ethnicity, birth year (±1 years), date of blood draw (±6 months),
time of blood draw (±2 hours), and fasting hours (0–<6, 6–<8, 8–<10, and 10+ hours).
Of 467 cases, 329 had fasting blood samples available for analysis. Of their 658 matched
controls with fasting blood, 656 had samples available for analysis. Therefore, our analysis
included 329 matched sets, 327 with 2 controls and 2 with 1 control. There were 62 advanced
or high grade prostate cancer cases, 213 localized cases without a high grade tumor and 54
cases where this staging could not be determined due to missing values.
2.3. Plasma 25-hydroxyvitamin D assay
Plasma 25(OH)D was measured according to the manufacturer's directions utilizing an
immunoassay kit purchased from Immunodiagnostic Systems, Ltd. (Fountain Hills, AZ).
Samples from matched cases and controls were analyzed in the same analytical batch. One
hundred and twenty-nine samples from 46 quality control plasma pools were analyzed blindly
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with the study samples. The within-batch coefficient of variation was 2% and the across-batch
coefficient of variation was 3%.
2.4. Statistical analyses
Selected characteristics were tested between cases and controls by the t-test for continuous
variables and the chi-square test for categorical variables. Subjects were divided into quartiles
determined by the overall distribution of plasma 25(OH)D in both cases and controls. Also,
clinically defined cutpoints (<20, 20–<30, 30–<50, and ≥50 ng/ml) were used in order to
evaluate the risk of prostate cancer for vitamin D deficient (<20 ng/ml) or insufficient level
(20–<30 ng/ml)21 as well as higher level. Odds ratios (ORs) and 95% confidence intervals
(95% CIs) were estimated using conditional logistic regression where matched sets were the
strata to account for the matching criteria given above. We entered age at blood draw, fasting
hours, and season of blood draw (winter: December - February; spring: March - May; summer:
June - August; and fall: September - November) to account for any possible systematic
differences within matched sets, in addition to adjustment for family history of prostate cancer
(yes/no), body mass index (BMI, <25, 25–<30, ≥30 kg/m2), education (years of schooling),
and physical activity (hours spent in moderate or vigorous activity per day), as these variables
were found previously to affect risk. Other potential confounders including calcium and
vitamin D intake from foods and/or supplements were evaluated, but were not included in the
models because they did not alter the association. Dose-response was tested using a trend
variable assigned the median of the appropriate quartile. The analyses were repeated separately
by tumor stage/grade. Two-sided P values less then 0.05 were considered significant. All
analyses were performed using SAS software, version 9.1 (SAS Institute Inc., Cary, NC).
3. Results
The matching characteristics, as well as years of education, physical activity level, and BMI,
were similar between cases and controls but family history of prostate cancer differed (13%
vs. 8 %, respectively, P = 0.01) (Table 1). Mean plasma 25(OH)D concentrations did not differ
statistically between cases (34.0 ng/ml) and controls (33.1 ng/ml). However, mean
concentrations were higher in participants living in Hawaii than in California. Mean
concentrations were highest in cases in the summer (35.3 ng/ml) and in controls in the fall
(36.7 ng/ml), but the differences were not great. Also, means of plasma 25(OH)D concentration
with adjustment for age, BMI, and physical activity were significantly different across racial/
ethnic groups (P < 0.001); adjusted means among controls were 26.3 ng/ml in African
Americans, 31.1 ng/ml in Latinos, 36.9 ng/ml in Japanese Americans, 37.7 ng/ml in Native
Hawaiians, and 45.6 ng/ml in Whites (data not shown).
No association was found between quartiles of plasma 25(OH)D and prostate cancer risk
overall (Table 2). Adjusting for family history of prostate cancer, BMI, education, and physical
activity did not change the estimate substantially. When we used clinically defined cutpoints
for plasma 25(OH)D and fixed the range of 30–<50 ng/ml as the reference group, there was
no increased risk for deficient (OR for <20 ng/ml = 1.10, 95% CI = 0.68-1.78) or insufficient
levels (OR for 20–<30 ng/ml = 1.04, 95% CI = 0.73-1.48) of plasma 25(OH)D, while there
was a suggestive increased risk for the higher 25(OH)D concentration (OR for ≥50 ng/ml =
1.52, 95% CI = 0.92-2.51). When we ran the models for localized and advanced or high grade
cases separately, we found no significant relation for either (data not shown).
4. Discussion
In this nested case-control study within the Multiethnic Cohort, we did not observe a significant
association between plasma 25(OH)D levels and prostate cancer risk overall. Indeed, we
observed a nonsignificant increased risk of total prostate cancer for high 25(OH)D
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concentration (≥50 ng/ml). We found no significant associations with advanced or high grade
cancer.
An IARC Working Group conducted a meta-analysis of 7 prospective studies, and found no
association between circulating 25(OH)D and prostate cancer; the relative risk for an increase
of l ng/ml unit of serum 25(OH)D was 0.998 (95% CI = 0.992-1.005).17 Adding the present
study, as well as other recent prospective studies showing no association between circulating
25(OH)D and prostate cancer in Finnish men8 and in the European Prospective Investigation
into Cancer and Nutrition22 would clearly not alter the result of this meta-analysis. In fact, two
studies observed an increased risk with higher 25(OH)D levels, especially for more aggressive
disease, 7,23 which was contrary to the hypothesis that vitamin D is protective against prostate
cancer.
Plasma 25(OH)D concentrations in our study population (33.1 ng/ml in the controls) were
higher than reported for the US male population covering similar age groups: 24.8 ng/ml in
men 50-69 years and 24.0 ng/ml in men ≥70 years.24 Using the cutoff of 20 ng/ml,21 16.1 %
of our study subjects would be considered vitamin D deficient, which is lower than in the
general US male population (27.0% of men 50-69 years and 26.6% of men ≥70 years).24
However, since methods for assessment of blood 25(OH)D have not been standardized, such
comparison between studies may not be reliable.17 Nonetheless, since our subjects are residents
in Hawaii and California (primarily Los Angeles County) where sunlight is abundant all year
round, circulating vitamin D levels might be expected to be higher than in men living at higher
latitudes. Thus, it is possible that we did not observe any association between 25(OH)D and
prostate cancer because of the small number of participants with low plasma 25(OH)D
concentrations. For instance, Ahonen and colleagues12 found an elevated risk of prostate cancer
only for men with 25(OH)D levels below 16 ng/ml, whereas only 6.9% of our subjects had
such low levels.
Racial/ethnic differences in 25(OH)D concentrations among our study population are
consistent with other reports for the US population; for example, non-Hispanic whites had
higher concentrations than did Mexican Americans and non-Hispanic Blacks.25 This is also
consistent with the fact that people with more extensive skin pigmentation have lower plasma
25(OH)D concentrations.18 When we examined African American men separately, who had
the lowest mean values of 25(OH)D and the largest number of cases in our study (n = 136),
we still did not observe any effect of low vitamin D status on prostate cancer development (OR
for <20 vs. ≥30 ng/ml = 1.03, 95% CI = 0.64-1.66). However, it is premature to draw any
conclusions regarding race/ethnic-specific associations in this study due to the limited number
of cases in each ethnic group for the different exposure levels. Few other studies examined
circulating vitamin D levels related to prostate cancer risk among non-White populations.
Another study of Japanese Americans living in Hawaii, in which the median concentration of
25(OH)D (41.6 ng/ml) was higher than in the Japanese men in our study (median = 34.4 ng/
ml), found no association between vitamin D metabolites and prostate cancer risk.13
The study's strengths include a prospective design, which minimized the chance that the disease
influenced health-related behaviors (such as dietary practices and screening for prostate cancer)
in the cases, and participants with diverse racial/ethnic backgrounds. Nevertheless, there are
several limitations to consider. We measured 25(OH)D using only a one-time plasma sample
and thus it may not reflect long-term circulating vitamin D status. However, a validation study
has shown a relatively high correlation coefficient (0.70) for two measures of 25(OH)D over
a three year period.10 The majority of the cases had early stage disease which limited our ability
to detect an effect of circulating 25(OH)D on tumor progression. Also, statistical power was
limited for race/ethnic-specific analyses, due to the limited number of cases. The time between
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blood draw and tumor diagnosis (mean = 1.9 years) was relatively short, and thus preclinical
disease might have influenced circulating vitamin D status in some cases.
In conclusion, findings from this prospective study of men in the Multiethnic Cohort do not
support the hypothesis that vitamin D protects against prostate cancer. Further follow-up is
warranted to determine whether the findings are consistent across ethnic groups.
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Table 1
Characteristics of prostate cancer cases and controls in the Multiethnic Cohort Study
Cases Controls P valuea
n 329 656
Age at blood draw, y 68.9 ± 7.1 68.7 ± 7.2 0.77
Fasting hours prior to blood draw 13.6 ± 2.5 13.8 ± 2.6 0.25
Education, y 14.0 ± 2.7 13.9 ± 2.9 0.53
Body mass index, kg/m2 26.1 ± 3.9 26.3 ± 4.0 0.52
Physical activity, hours/dayb 1.33 ± 1.44 1.24 ± 1.34 0.32
Family history of prostate cancer, (%) 13.1 8.1 0.01
Ethnicity, n (%)
 African Americans 136 (41.3) 272 (41.5) 1.00
 Native Hawaiians 12 (3.7) 23 (3.5)
 Japanese Americans 74 (22.5) 148 (22.6)
 Latinos 52 (15.8) 104 (15.9)
 Whites 55 (16.7) 109 (16.6)
Plasma 25-hydroxyvitamin D, ng/ml 34.0 ± 15.1 33.1 ± 15.5 0.86
 Study location
   Hawaii 43.2 ± 17.6 42.3 ± 17.4 0.65
   California 28.7 ± 11.2 27.8 ± 10.4 0.30
 Season of blood drawc
   Winter 32.1 ± 14.9 31.7 ± 14.0 0.84
   Spring 33.5 ± 17.6 31.5 ± 15.7 0.34
   Summer 35.3 ± 15.9 32.3 ± 12.2 0.14
   Fall 34.9 ± 13.3 36.7 ± 17.2 0.36
Data shown as mean ± SD unless specified otherwise
a
Tested by t-test (means) and chi-square test (percentages).
b
Hours spent in moderate or vigorous activity per day
c
The season categories were defined as winter: December - February; spring: March - May; summer: June - August; and fall: September - November.
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